| Project/Area Number |
24790529
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
SATO Hiromi 千葉大学, 薬学研究科(研究院), 助教 (30506887)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 薬物耐性 / sunitinib / 腎細胞癌 / 悪性中皮腫 / connexin / P-gp / がん薬物療法 / 併用効果 / エピジェネティック治療薬 / TKI / 薬剤耐性 / ABCG2 |
|---|
| Research Abstract |
We aimed to search an appropriate drug which sensitize sunitinib efficacy in renal cell carcinoma (RCC). Finally epigenetic drugs (sodium butyrate, TSA) came out as good combination partners via blockage of RTK signaling which is sunitinib targeted pathway, upregulation of anti-tumor factor of RCC, connexin, or cell cycle regulation. Another candidate was multi drug resistance improving drug (elacridar) via inhibition of drug efflux pump, p-glycoprotein. Furthermore, it has been shown that connexin could also improve sunitinib resistance in malignant mesothelioma cells.
|
